Found 291 clinical trials
An investigational biologic medication for the treatment of uncontrolled hives despite antihistamine use.
5 Clinic visits over 40 weeks testing a self injected investigational medication versus placebo for the treatment of uncontrolled hives despite antihistamines. You will remain on your current antihistamines while in the study.
- 115 views
- 23 Nov, 2020
- 1 location
AEWS07B1: Collecting and Storing Biological Samples From Patients with Ewing Sarcoma
AEWS07B1: Collecting and Storing Biological Samples From Patients with Ewing Sarcoma
- 60 views
- 08 Nov, 2020
- 1 location
COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 – Canada
The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements. This is an interventional active-controlled, open-label, randomized Phase 3 study to compare the efficacy and safety of luspatercept …
- 22909 views
- 04 May, 2022
- 10 locations
Study to Assess the Immunogenicity and Safety of GSK's Meningococcal Group B Vaccine When Administered Concomitantly With GSK's Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age
The purpose of this study is to evaluate the immunogenicity, safety and tolerability of rMenB+OMV NZ and MenACWY vaccines when concomitantly administered to healthy subjects 16-18 years of age.
- 27 views
- 29 Apr, 2022
- 24 locations
An Investigation of Oral BT051 in Subjects With Moderately to Severely Active Ulcerative Colitis (UC) (SCOUT)
This is a randomised, double-blind, placebo-controlled study to assess the safety and tolerability of multiple ascending doses of BT051 in subjects with moderately to severely active ulcerative colitis. Subjects will be randomised using a 3 active:1 placebo ratio to 3 ascending dose cohorts of 8 subjects and will be dosed …
- 0 views
- 11 May, 2022
- 6 locations
RA-PRO PRAGMATIC TRIAL
The 2015 ACR RA treatment guideline, based on widely acknowledged low to moderate quality evidence, recommends adding TNFi-biologic, non-TNFi biologic or a tsDMARD to MTX in MTX-IR patients with active RA.24 In practice, most patients receive a TNFi-biologic first. This is not based on solid evidence, but on arbitrary algorithms …
- 0 views
- 27 Oct, 2021
- 1 location
Clinical and Biological Digestive Peritoneal Carcinomatosis Data Base From the French National Network of Peritoneal Surface Malignancies (BIG-RENAPE)
To access to good quality biological samples is a prerequisite for high level translational research. The BIG-RENAPE study has been established by the French hyperthermic intraperitoneal chemotherapy centers involved in the management of peritoneal surface malignancies. The main BIG-RENAPE study aim is to create a large multicentric and prospective repository …
- 1 views
- 24 Feb, 2022
- 1 location
Biological & Fonctional Signatures for Muscle Failures, Aged People & Personalized Physical Activity (BioFaSt)
Physical activity is one of the most effective therapeutic interventions for frailty, sarcopenia or dynapenia. The benefits of physical activity processes are already widely documented. Typically, researchers want to understand the average response to an intervention to determine its overall effectiveness. However, sports trainers have understood it for a long …
- 0 views
- 12 May, 2022
- 1 location
Creation of a Prospective Cohort of Healthy and Sick Subjects and of a Collection of Associated Biological Resources, for the Study of the Immune System and of Its Genetic and Environmental Determinants. (CoSImmGEn)
CoSImmGEn is a protocol set up to respond to the current lack of healthy and sick population cohorts. Biological resources from these cohorts allow researchers to study the immune system and its genetic and environmental determinants. Those cohorts and collections are open not only to the Pasteurian community but also …
- 109 views
- 04 Feb, 2022
- 3 locations
Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection
A First-Time-In-Human study on GSK's therapeutic vaccines to evaluate the reactogenicity, safety, immunogenicity and efficacy on reduction of serum HBV surface antigen in HBV suppressed subjects under nucleo(s)tide treatment.
- 39 views
- 23 Mar, 2022
- 33 locations